^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Anpingxi (ripertamab)
i
Other names: SCT400, SCT-400, SCT 400
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
CSPC Pharma, Sinocelltech
Drug class:
CD20 inhibitor
Related drugs:
2ms
Efficacy and Safety of Ripertamab With or Without Other Drugs in B-cell Non-Hodgkin's Lymphomas (ChiCTR2400087275)
P=N/A, N=400, Recruiting, Institute of Hematology and Oncology, Harbin The First Hospital; Institute of Hematology and Oncology, Harbin The First Hospital
New trial • Real-world evidence • Real-world
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Anpingxi (ripertamab)
7ms
Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD (clinicaltrials.gov)
P3, N=81, Not yet recruiting, Air Force Military Medical University, China
New P3 trial • Combination therapy
|
prednisone • Anpingxi (ripertamab)
almost2years
A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera) in patients with CD20-positive B-cell non-Hodgkin lymphoma. (PubMed, Chin J Cancer Res)
The incidences of treatment-emergent adverse events and treatment-related adverse events were also comparable between the two groups. In this study, the PK, PD, immunogenicity, and safety profile of ripertamab (SCT400) were similar to rituximab (MabThera) in Chinese patients with CD20-positive B-cell NHL.
P2 data • PK/PD data • Journal
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
|
CD20 positive • CD19 positive
|
Rituxan (rituximab) • Anpingxi (ripertamab)
over2years
Comparison of Efficacy and Safety of Ripertamab (SCT400) Versus Rituximab (Mabthera ) in combination with CHOP in Patients with Previously Untreated CD20-positive Diffuse Large B-cell Lymphoma: A Randomized, Single-blind, Phase III Clinical Trial. (PubMed, Hematol Oncol)
This study demonstrated that S-CHOP was not inferior to R-CHOP in the first-line treatment of CD20-positive DLBCL Chinese patients in efficacy, safety and immunogenecity. S-CHOP could be an alternative first-line treatment for DLBCL, and was expected to be a cost-effective alternative to rituximab and offer an opportunity to increase access to the biologics.
P3 data • Journal • Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • Anpingxi (ripertamab)
Share via
